title: Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.
abstract: Children of mothers infected with human immunodeficiency virus type 1 (HIV-1) were immunized at birth and at 1, 3, and 5 months with 1 of 3 doses of recombinant gp120 vaccines prepared from SF-2 or MN strains of HIV-1. A total of 126 children were not infected; 21 received adjuvant only. Vaccine recipients developed lymphoproliferative responses on >/=2 occasions, responding more often to homologous HIV-1 antigens than did adjuvant recipients (56% vs. 14%; P<.001). Responses were appreciated after 2 immunizations and were maintained for >84 weeks after the last immunization. An accelerated immunization schedule (birth, 2 weeks, 2 months, and 5 months) with the lowest dose of the SF-2 vaccine produced responses in all 11 vaccinees by 4 weeks. Responses to heterologous envelope antigens were also detected. Immune responses to vaccination are achievable at an age when some infection (perinatal or breast milk exposure related) may be prevented.
authors.affiliation: The Saul Krugman Division of Infectious Diseases and Immunology, New York University Medical School, New York, NY 10016, USA. borkow01@mcgc16.med.nyu.edu
authors.forename: W
authors.initials: W
authors.lastname: Borkowsky
authors.forename: D
authors.initials: D
authors.lastname: Wara
authors.forename: T
authors.initials: T
authors.lastname: Fenton
authors.forename: J
authors.initials: J
authors.lastname: McNamara
authors.forename: M
authors.initials: M
authors.lastname: Kang
authors.forename: L
authors.initials: L
authors.lastname: Mofenson
authors.forename: E
authors.initials: E
authors.lastname: McFarland
authors.forename: C
authors.initials: C
authors.lastname: Cunningham
authors.forename: A M
authors.initials: AM
authors.lastname: Duliege
authors.forename: D
authors.initials: D
authors.lastname: Francis
authors.forename: Y
authors.initials: Y
authors.lastname: Bryson
authors.forename: S
authors.initials: S
authors.lastname: Burchett
authors.forename: S A
authors.initials: SA
authors.lastname: Spector
authors.forename: L M
authors.initials: LM
authors.lastname: Frenkel
authors.forename: S
authors.initials: S
authors.lastname: Starr
authors.forename: R
authors.initials: R
authors.lastname: Van Dyke
authors.forename: E
authors.initials: E
authors.lastname: Jimenez
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007223:Infant; D007231:Infant, Newborn; D008213:Lymphocyte Activation; D011994:Recombinant Proteins / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic